The last time I spoke about Omeros Corporation (OMER) it was in a Seeking Alpha article entitled "Omeros: FDA Appeal On Nasoplimab And Several 2023 Catalysts On Deck." Since then, it has faced several ...

Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

A case report describes a 14-year-old boy whose common cold virus triggered atypical hemolytic uremic syndrome with severe skin necrosis that required surgical debridement after drug therapy failed.

SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...

Complement pathway proteins are involved in immunoglobulin A-containing immune complex (IgA-IC) formation and deposition in the kidneys. Elevated complement factor H-related protein 1 (CFHR1) may be a ...